Edgewise Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
EWTX$48.74+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · As of · · As of | ||||||
| · · September 30, · · December 31, | ||||||
| · · 2026 · · 2025 | ||||||
| Assets · · (unaudited) · · | ||||||
| Current assets · · · · · | ||||||
| Cash and cash equivalents | | $68,680 | | $61,148 | ||
| Marketable securities, available for sale | | 1,675,213 | | 468,961 | ||
| Prepaid expenses and other assets | | 28,576 | | 13,276 | ||
| Total current assets | | 1,772,469 | | 543,385 | ||
| | | | | | | |
| Property and equipment, net | | 6,333 | | 7,831 | ||
| Operating lease right-of-use asset | | | 1,218 | | | 1,387 |
| | | | | | | |
| Total assets | | $1,780,020 | | $552,603 | ||
| | | | | | | |
| Liabilities and stockholders' equity | | | | | ||
| | | | | | | |
| Current liabilities | | | | | ||
| Accounts payable | | $9,639 | | $6,006 | ||
| Accrued compensation | | 8,805 | | 12,430 | ||
| Accrued other expenses | | 15,736 | | 7,920 | ||
| Accrued taxes | | | 108,901 | | | — |
| Operating lease liability, current portion | | | 1,025 | | | 1,014 |
| Total current liabilities | | 144,106 | | 27,370 | ||
| Operating lease liability, net of current portion | | | 2,358 | | | 2,976 |
| Other long term liabilities | | | 888 | | | — |
| | | | | | | |
| Total liabilities | | 147,352 | | 30,346 | ||
| | | | | | | |
| Commitments and contingencies (see note 5) | | | | | ||
| | | | | | | |
| Stockholders' equity: | | | | | ||
| Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of September 30, 2026 and December 31, 2025 | | | — | | | — |
| Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 109,457,922 shares and 106,249,579 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | | 10 | | 10 | ||
| Additional paid-in capital | | 1,124,820 | | 1,067,941 | ||
| Accumulated other comprehensive (loss) income | | | (5,602) | | | 677 |
| Retained earnings (accumulated deficit) | | 513,440 | | (546,371) | ||
| Total stockholders' equity | | 1,632,668 | | 522,257 | ||
| | | | | | | |
| Total liabilities and stockholders' equity | | $1,780,020 | | $552,603 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.